I-Linagliptin CAS 668270-12-0 Purity ≥99.0% (HPLC) Isithombe Esifakiwe Sefekthri

I-Linagliptin CAS 668270-12-0 Purity ≥99.0% (HPLC) Factory

Incazelo emfushane:

Igama leKhemikhali: Linagliptin

I-CAS: 668270-12-0

Ubumsulwa: ≥99.0% (HPLC)

Ukubukeka: I-Crystalline Powder Emhlophe noma Engamhlophe

I-Linagliptin yokwelashwa kwesifo sikashukela sohlobo II

I-API, Ikhwalithi Ephezulu, Ukukhiqizwa Kwezohwebo

E-Mail: alvin@ruifuchem.com

Thumela i-imeyili kithi

Imininingwane Yomkhiqizo

Imikhiqizo Ehlobene

Omaka bomkhiqizo

Incazelo:

Ukunikezwa Komkhiqizi, Ukuhlanzeka Okuphezulu, Ukukhiqizwa Kwezohwebo
Igama leKhemikhali: Linagliptin
I-CAS: 668270-12-0

Chemical Properties:

Igama Lekhemikhali	I-Linagliptin
Omqondofana	BI-1356;8-[(3R)-3-Amino-1-piperidinyl]-7-(2-butynyl)-3,7-dihydro-3-methyl-1-[(4-methyl-2-quinazolinyl)methyl]-1H I-purine-2,6-dione
Inombolo ye-CAS	668270-12-0
Inombolo yeCAT	I-RF-API105
Isimo Sesitoko	Esitokweni, Isikali Sokukhiqiza Sifinyelela Kumathani
I-Molecular Formula	I-C25H28N8O2
Isisindo samangqamuzana	472.54
I-Melting Point	197.0 ukuze 200.0 ℃
Ukuncibilika	I-Soluble ku-DMSO
Ibhrendi	I-Ruifu Chemical

Imininingwane:

Into	Imininingwane
Ukubukeka	I-Crystalline Powder Emhlophe noma Engamhlophe
I-NMR	Ihambisana Nesakhiwo
Ukuhlanzeka / Indlela Yokuhlaziya	≥99.0% (HPLC)
Ukulahlekelwa Ekumisweni	≤0.50%
Izinsalela ekushiseni	≤0.10%
Izinsimbi Ezisindayo	≤10ppm
Izinto Ezihlobene
Ukungcola Okukodwa	≤0.50%
Ukungcola Okuphelele	≤1.0%
Isomer	≤0.15%
Izincibilikisi Ezisele
I-Methanol	≤3000ppm
Isopropanol	≤5000ppm
I-DMF	≤800ppm
I-Dichloromethane	≤600ppm
Izinga Lokuhlola	I-Enterprise Standard
Ukusetshenziswa	I-API

Iphakheji nesitoreji:

Iphakheji: Ibhodlela, isikhwama se-Aluminium foil, 25kg/Cardboard Drum, noma ngokwezidingo zekhasimende.

Isimo Sesitoreji:Gcina ezitsheni ezivaliwe endaweni epholile neyomile;Vikela ekukhanyeni nakumswakama.

Izinzuzo:

I-FAQ:

Isicelo:

I-Linagliptin (CAS: 668270-12-0) iyi-DPP-4 inhibitor eyakhiwe ngu-Boehringer Ingelheim ekwelapheni uhlobo lwesifo sikashukela sohlobo II.Izici ezimbili ze-pharmacological ezehlukanisa i-linagliptin kwamanye ama-DPP-4 inhibitors ukuthi inephrofayili ye-pharmacokinetic engaqondile futhi ayiqedwa ngokuyinhloko uhlelo lwezinso.I-Linagliptin (kanye ngosuku) yagunyazwa yi-US FDA ngomhlaka-2 Meyi 2011 ukuze kwelashwe uhlobo lwesifo sikashukela sohlobo II.Imakethwa nguBoehringer Ingelheim noLilly.I-Linagliptin, ethengiswa ngaphansi kwegama lomkhiqizo iTradjenta phakathi kwabanye.Isetshenziswa kanye nokuzivocavoca kanye nokudla.